Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Sjögren’s Syndrome in Kids: Diagnostic Challenges & Treatment Options

Sara M. Stern, MD, Matthew L. Basiaga, DO, MSCE, & Scott M. Lieberman, MD, PhD  |  Issue: January 2020  |  January 17, 2020

Treatment

Treatment goals for Sjögren’s syndrome in childhood is to prevent progression of the disease, decrease pain and enable typical growth and development. Currently, there is no literature about the efficacy of medication to slow disease progression in childhood Sjögren’s syndrome.

The most common medication used is hydroxychloroquine, which is possibly beneficial in children and has minimal side effects. In adults, a decrease in extraglandular symptoms seems to occur in patients treated with hydroxychloroquine.7 No large studies have been completed with children.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

During acute exacerbations of parotitis, short courses of oral or intravenous steroids can aid in symptomatic management. Sialagogues have also been used to help increase salivary flow during acute flares of parotitis. Methotrexate and hydroxychloroquine have been used in an attempt to prevent recurrent flares of parotitis.

Multiple immunomodulatory agents, including abatacept, rituximab, myco­phenolate mofetil, azathioprine, belimumab and tumor necrosis factor inhibitors, have been used to treat specific extraglandular symptoms in children with Sjögren’s syndrome.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Another vital aspect of children’s care is their oral and ocular health. Children should be referred to oral and ocular healthcare providers. Their dental exams should include frequent cleanings and fluoride treatments (every three to six months). Sicca symptoms may be alleviated with stimulants (e.g., sugar-free gum or sugar-free sour candies) to increase saliva secretion or with saliva replacements. Nonselective muscarinic agonists, such as pilocarpine, have also been tried in severe cases of pediatric sicca.

Yearly ocular exams should be performed, monitoring conjunctival and corneal changes from chronic dryness and/or ocular inflammation. Artificial tears are commonly used for symptomatic relief in children suffering symptoms of dry eyes. For children who have evidence of ocular damage from kerato­conjunctivitis sicca, topical anti-inflammatory agents may be beneficial.

Due to the complexity of treating these children, a multidisciplinary team is often needed.

Prognosis

Long-term studies of individuals diagnosed with Sjögren’s syndrome during childhood have not been performed. Based on our collective clinical experience, we expect childhood Sjögren’s syndrome will progress over time to exhibit classic sicca symptoms common in adults. Some children develop exocrine gland dysfunction and sicca symptoms during childhood. However, for those who do not, the timing of progression may be years or decades.

While extra-glandular manifestations may be more common in childhood Sjögren’s syndrome, quality of life in adults is more associated with dryness, pain and fatigue.12

Adults with Sjögren’s syndrome are at increased risk for developing lymphoma. Although lymphoma development has been reported in some children with Sjögren’s syndrome, whether the risk is similar to or greater than that in adults is not yet known.13,14

Page: 1 2 3 4 5 | Single Page
Share: 

Filed under:ConditionsSjögren’s Disease Tagged with:BiomarkersClassification CriteriaPediatric RheumSjogren's

Related Articles

    Systemic Sjögrens: More Than a Sicca Disease

    November 1, 2014

    Differences in its epidemiologic, clinical and immunologic features underscore need for a homogeneous diagnostic and therapeutic approach

    Clinical Guidelines for Sjögren’s Syndrome Focus on Biologics, Fatigue, Inflammatory Musculoskeletal Pain

    June 15, 2017

    The first clinical practice guidelines for Sjögren’s syndrome have been released, the culmination of an initiative by the Sjögren’s Syndrome Foundation.1 These standard-of-care recommendations are intended to provide consistency in practice patterns, inform coverage and reimbursement policies, lead to the design and implementation of educational programs, highlight the needs for future research and fill a…

    Researchers Look for Therapeutic Clues to Sjögrens Syndrome in Neural Pathways

    November 1, 2013

    Beyond biologic agents, scientists study cytokines, chemokines, and the interface between inflammatory and neural/secretory pathways

    Photoroyalty / shutterstock.com

    Race As a Risk Factor for Sjögrens Syndrome

    October 19, 2020

    A new study in Arthritis Care & Research highlights potential differences in incidence, the presentation of prominent symptoms and laboratory findings in African Americans and Native Americans with Sjögren’s syndrome compared with white populations. Native Americans appear to be at higher risk of the disease, although they often display fewer of the classic symptoms. Importantly,…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences